LOSS OF THE INHIBITORY RECEPTOR CD85J/LILRB1 ON MALIGNANT PLASMA CELLS: FROM MGUS TO SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Ester Lozano, 133250

PROTEIN KINASE CK1A INACTIVATION IN MULTIPLE MYELOMA EMPOWERS LENALIDOMIDE INDUCED CYTOTOXICITY AND CELL CYCLE ARREST

EHA Library, Sabrina Manni, 133251

QUANTIFICATION OF CYCLIN D1, CYCLIN D2, IKAROS, AIOLOS AND CEREBLON PROTEINS BY CAPILARY IMMUNOASSAY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND ANALYSIS OF THEIR IMPACT ON PATIENT SURVIVAL

EHA Library, Irena Misiewicz-Krzeminska, 133252

DEFERASIROX INDUCES APOPTOSIS THROUGH INHIBITION OF ONCOGENIC PYK2/BETA-CATENIN SIGNALING IN MULTIPLE MYELOMA CELLS

EHA Library, Yusuke Kamihara, 133253

DEVELOPMENT AND IMPLEMENTATION OF A HIGH-THROUGHPUT SEQUENCING BASED, CLINICALLY-FOCUSED, COMPREHENSIVE GENOMIC CHARACTERISATION OF MYELOMA WITHIN A MOLECULAR DIAGNOSTIC SERVICE

EHA Library, Piers Blombery, 133254

DYNAMIC EVOLUTION OF COPY NUMBER ABERRATIONS ACCOMPANIES DISEASE RELAPSE IN MULTIPLE MYELOMA

EHA Library, Martin Kaiser, 133255

IMPACT OF CYTOGENETIC RISK STATUS ON EFFICACY AND SAFETY OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN THE GLOBAL TOURMALINE-MM1 STUDY

EHA Library, Hervé Avet-Loiseau, 133256

HIGH CUT-OFF HAEMODIALYSIS (HCO-HD) DOES NOT IMPROVE OUTCOMES IN MYELOMA CAST NEPHROPATHY: RESULTS OF EUROPEAN TRIAL OF FREE LIGHT CHAIN REMOVAL BY EXTENDED HAEMODIALYSIS IN CAST NEPHROPATHY (EULITE)

EHA Library, Mark Cook, 133257

OPROZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (OPOMD) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): INITIAL RESULTS OF A PHASE 1B STUDY (NCT01999335)

EHA Library, Jatin Shah, 133258

PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Philippe Moreau, 133259

A PHASE IB STUDY OF THE AKT INHIBITOR AFURESERTIB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS WITH LONG TERM FOLLOW-UP

EHA Library, Suzanne Trudel, 133260

UPDATED DATA FROM A PHASE II DOSE FINDING TRIAL OF SINGLE AGENT ISATUXIMAB (SAR650984, ANTI-CD38 MAB) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Meletios Dimopoulos, 133261

CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: ANALYSIS OF RESPONSE AND PROGRESSION-FREE SURVIVAL HAZARD RATIO OVER TIME

EHA Library, Meletios Dimopoulos, 133262

THE SKY92 PROGNOSTIC MARKER IS VALIDATED IN EIGHT MULTIPLE MYELOMA CLINICAL DATASETS

EHA Library, Martin van Vliet, 133263

A PHASE 1B/2 STUDY OF SELINEXOR IN COMBINATION WITH BACKCONE THERAPIES FOR TREATMENT OF RELAPSED/REFACTORY MULTIPLE MYELOMA

EHA Library, Nizar J Bahlis, 133264

A PHASE IB DOSE-ESCALATION TRIAL OF ISATUXIMAB (SAR650984, ANTI-CD38 MAB) PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): INTERIM RESULTS FROM 2 NEW DOSE COHORTS

EHA Library, Ai-Min HUI, 133265

MOR202 ALONE AND IN COMBINATION WITH POMALIDOMIDE OR LENALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DATA FROM CLINICALLY RELEVANT COHORTS FROM A PHASE I/IIA STUDY

EHA Library, Marc S. Raab, 133266

ELOTUZUMAB + LENALIDOMIDE/DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: ELOQUENT-2 POST-HOC ANALYSIS OF PFS AND TUMOR REGROWTH BY TIME FROM DIAGNOSIS AND PRIOR LINES OF THERAPY

EHA Library, Meletios Dimopoulos, 133267

FINAL PHASE 2 STUDY DATA OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Antonio Palumbo, 133268

PRECISION AS PART OF THE ANALYTICAL VALIDATION OF THE SKY92 HIGH RISK SIGNATURE AND THE MMPROFILER ASSAY

EHA Library, Martin van Vliet, 133269

RISK STRATIFICATION BY SKY92+ISS OUTPERFORMS IFISH MARKERS T(4;14) AND DEL(17P) IN MULTIPLE MYELOMA

EHA Library, Martin van Vliet, 133270

CONSOLIDATION WITH BORTEZOMIB AND LENALIDOMIDE POST-ASCT WITHOUT DEXAMETHASONE AND BISPHOSPHONATES: FINAL ANALYSIS OF A PROSPECTIVE STUDY IN NEWLY DIAGNOSED MYELOMA PATIENTS

EHA Library, Evangelos Terpos, 133271

LOW INCIDENCE OF SKELETAL-RELATED EVENTS AT THE TIME OF FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVED BORTEZOMIB-BASED REGIMENS AS FIRST LINE TREATMENT

EHA Library, Evangelos Terpos, 133272

PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Tine Casneuf, 133273

CONCURRENT INHIBITION OF PI3K/MTOR AND JAK1/JAK2 PATHWAYS PROMPTS COMPLETE DEPHOSPHORYLATION OF STAT5 PROVIDING SYNERGISTIC ACTIVITY IN MPN MODELS

EHA Library, Manjola Balliu, 133274

ACE-1332 (TGFB LIGAND TRAP) INHIBITS ELEVATED TGFΒ1 SIGNALING AND REDUCES FIBROSIS IN A MURINE MODEL OF MYELOFIBROSIS

EHA Library, Rajasekhar NVS Suragani, 133275

TARGETING OF BRD4 AS A NOVEL THERAPEUTIC CONCEPT IN JAK2 V617F+ MPN

EHA Library, Alexandra Keller, 133276

LNK MUTATIONS IN FAMILIAL MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Elisa Rumi, 133277

HOMOZYGOUS CALRETICULIN MUTATIONS IN PATIENTS WITH MYELOFIBROSIS LEAD TO ACQUIRED MYELOPEROXIDASE DEFICIENCY

EHA Library, Alexandre , 133278

CHARACTERISATION OF THE INFLAMMATORY MICROENVIRONMENT IN MYELOPROLIFERATIVE NEOPLASMS AND ITS FUNCTIONAL IMPACT ON STEM AND PROGENITOR CELLS

EHA Library, Nina Friesgaard Oebro, 133279

MESENCHYMAL STROMAL CELLS (MSC) FROM HIGH-GRADE BONE MARROW FIBROSIS PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (PH-NEG MPN) DISPLAY REDUCED CLONOGENICITY AND PROLIFERATION CAPACITY.

EHA Library, Benedetta Rambaldi, 133280

NEXT-GENERATION SEQUENCING IDENTIFIES MPL-TET2 MUTATED CLONES IN A SUBSET OF PATIENTS WITH JAK2V617F-POSITIVE MYELOFIBROSIS

EHA Library, Susann Schulze, 133281

THE INNATE AND ADAPTIVE IMMUNE SYSTEM IS SIGNIFICANTLY DYSREGULATED IN MYELOFIBROSIS: EVIDENCE OF A CENTRAL ROLE OF MUTATIONAL STATUS

EHA Library, Lucia Catani, 133282

SAFETY AND EFFICACY OF RUXOLITINIB IN PATIENTS WITH DIPSS INTERMEDIATE-1–RISK MYELOFIBROSIS (MF) FROM JUMP: AN OPEN-LABEL, MULTICENTER, SINGLE-ARM, EXPANDED-ACCESS STUDY

EHA Library, Francesco Passamonti, 133283

PHASE 3 TRIAL TEAM-ET IN 106 HIGH-RISK ESSENTIAL THROMBOCYTHEMIA PATIENTS, DEMONSTRATING NON-INFERIORITY OF ANATHROMB, A NOVEL, EXTENDED-RELEASE ANAGRELIDE FORMULATION, TO THE LICENSED COMPARATOR

EHA Library, Heinz Gisslinger, 133284

CLINICAL IMPACT OF ONCOGENETIC PROFILES IN SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NON-MAST CELL DISEASE.

EHA Library, Alberto Orfao, 133285

MUTATIONAL STUDY OF GENES INVOLVED IN MYELOFIBROSIS BY MASSIVE SEQUENCING

EHA Library, Ana Africa Martin Lopez, 133286

PHASE II STUDY OF LCL161, A SMAC MIMETIC, IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) OR POST-ESSENTIAL THROMBOCYTOSIS MYELOFIBROSIS (POST-ET MF

EHA Library, Naveen Pemmaraju, 133287

PREVENTION OF THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH HYDROXUYUREA PLUS PHLEBOTOMIES OR HYDROXYUREA ALONE

EHA Library, Alberto Alvarez-Larrán, 133288

RATE OF MALIGNANT TRANSFORMATION IN HIGH RISK ET DURING 5 YEARS OF FOLLOW-UP OF CYTOREDUCTIVE THERAPY

EHA Library, Gunnar Birgegard, 133289

MIDOSTAURIN (PKC412) IN INDOLENT SYSTEMIC MASTOCYTOSIS: A PHASE 2 TRIAL

EHA Library, Bart Span, 133290

RISK FACTORS (RF) FOR RELAPSE IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (RRHL) AFTER AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): A REAL-WORLD ANALYSIS IN GERMANY AND THE UNITED KINGDOM (UK)

EHA Library, Erin Zagadailov, 133291

BRENTUXIMAB VEDOTIN (BV) IN PATIENTS WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (RRHL): A UK AND GERMANY RETROSPECTIVE STUDY

EHA Library, Paul J Bröckelmann, 133292

REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN (BV) VS. OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RRHL) POST AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT)

EHA Library, Erin Zagadailov, 133293

ABDOMEN/PELVIS COMPUTED TOMOGRAPHY IN STAGING OF PEDIATRIC HODGKIN LYMPHOMA: IS IT ALWAYS NECESSARY?

EHA Library, Piero Farruggia, 133294

INCREASED CORONARY ARTERY CALCIUM SCORE AFTER RADIOTHERAPY IN HODGKIN LYMPHOMA SURVIVORS

EHA Library, Elena Van Leeuwen, 133295

THE LYMPHOMA ASSOCIATED MACROPHAGES-HODGKIN/REED-STERNBERG CELLS RATIO IS A POOR PROGNOSTIC FACTOR IN CLASSIC HODGKIN LYMPHOMA PATIENTS

EHA Library, Eva Kriegová, 133296

THE PROGNOSTIC ROLE OF BCL-2 EXPRESSION IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ASSESSED FOR CD68+ CELL COUNT.

EHA Library, Annarosa Cuccaro, 133297

AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT) IS HIGHLY EFFECTIVE IN RELAPSED NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL): A RETROSPECTIVE STUDY BY THE EBMT LYMPHOMA WORKING PARTY

EHA Library, Anna Sureda, 133298

BIOLOGICALLY MEANINGFUL CHANGES IN CYTOKINE AND CHEMOKINE PRODUCTION FOLLOWING IBRUTINIB THERAPY IN WALDENSTROM’S MACROGLOBULINEMIA.

EHA Library, Josephine Vos, 133299

A PHASE III STUDY OF OFATUMUMAB VS RITUXIMAB IN INDOLENT B-CELL NON-HODGKIN LYMPHOMA RELAPSED AFTER RITUXIMAB-CONTAINING THERAPY (HOMER): RESULTS OF THE INTERIM ANALYSIS

EHA Library, David MALONEY, 133300

A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA

EHA Library, Melissa Kuhn, 133301

LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB.

EHA Library, Owen O'Connor, 133302

THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED / REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF THE PHASE II AIM STUDY

EHA Library, Constantine S. Tam, 133303

IDELALISIB MONOTHERAPY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): EXPERIENCE THROUGH AN EARLY ACCESS PROGRAM IN EUROPE AND AUSTRALIA

EHA Library, Andrew J. Davies, 133304

PHASE 2A STUDY OF THE PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY, INDOLENT OR AGGRESSIVE LYMPHOMA

EHA Library, Martin Dreyling, 133305

PRELIMINARY SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DUVELISIB PLUS RITUXIMAB OR OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED CD20+ FOLLICULAR LYMPHOMA

EHA Library, Carla Casulo, 133306

SAFETY AND EFFICACY PROFILES OF CLARITHROMYCIN MONOTHERAPY IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL)

EHA Library, Andres Jose Maria Ferreri, 133307

A PHASE I STUDY IN T CELL LYMPHOMA PATIENTS TREATED WITH ANTI-CD70 SIMPLE ANTIBODY™ ARGX-110

EHA Library, Jean-Marie Michot, 133308

TO SCREEN BIOLOGICAL MARKER GENE ASSOCIATED WITH B CELL IN CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) PATIENTS

EHA Library, Limin Liu, 133309

MITOCHONDRIAL INHIBITION BY NICOTINAMIDE RIBOSIDE POTENTLY STIMULATES HEMATOPOIESIS AFTER TRANSPLANTATION VIA THE MITOCHONDRIAL UNFOLDED PROTEIN RESPONSE

EHA Library, Nicola Vannini, 133310

MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS

EHA Library, Mette Hazenberg, 133311

GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION INCREASES THE PROPORTION OF REGULATORY GAMMA DELT T CELLS

EHA Library, Li Xuan, 133312

PREACTIVATED MESENCHYMAL STROMAL CELLS IMPROVE T-CELL REGENERATION AFTER THEIR COTRANSPLANTATION WITH HEMATOPOIETIC STEM CELLS

EHA Library, Selim Kuci, 133313

EVIDENCE OF COMPLEMENT DYSREGULATION IN TRANSPLANT – ASSOCIATED THROMBOTIC MICROANGIOPATHY

EHA Library, Eleni Gavriilaki, 133314

FAMILY-DIRECTED CORD BLOOD BANKING FOR SICKLE CELL DISEASE: A 20-YEAR EXPERIENCE, ON BEHALF OF EUROCORD-MONACORD AND THE INTERNATIONAL SICKLE CELL DISEASE OBSERVATORY.

EHA Library, Hanadi El Ayoubi, 133315

CONSOLIDATION BY ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CR1 AGED 40-69 YEARS: A COMPARISON OF MYELOABLATIVE AND REDUCED INTENSITY CONDITIONING

EHA Library, Aniko Szabo, 133316

RELAPSED/REFRACTORY HIGH GRADE B CELL NON-HODGKIN LYMPHOMA: SHOULD ONGOING PET POSITIVITY PRECLUDE AUTOLOGOUS TRANSPLANTATION IN PATIENTS ATTAINING A CT RESPONSE TO SALVAGE CHEMOTHERAPY?

EHA Library, Nagah Elmusharaf, 133317

MARAVIROC CONCENTRATIONS ARE HIGHLY PREDICTIVE OF ACUTE GRAFT-VERSUS-HOST DISEASE IN REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Alex Ganetsky, 133318

HYPERACUTE GRAFT VERSUS HOST DISEASE: RISK FACTORS, OUTCOMES AND IMPACT OF TACROLIMUS/SIROLIMUS PROPHYLAXIS.

EHA Library, MD Caballero, 133319

REDUCED INTENSITY CONDITIONING TRANSPLANTATION (RIC) AS PART OF FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE II MINI ALLO TRIAL (CRUK: C7627/A9080)

EHA Library, Simon Rule, 133320

THE ROLL OF HYPOMETHYLATING AGENTS IN MYELOID RELAPSES AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT.

EHA Library, Felix Lopez Cadenas, 133321

IMPROVED CLINICAL OUTCOMES OF GBM/GPB MIXTURE HAPLOIDENTICAL TRANSPLANTATION WHEN COMPARED TO A PROPENSITY SCORE-MATCHED GPB HAPLOIDENTICAL TRANSPLANTATION: A MULTICENTER STUDY

EHA Library, Xiaojun Huang, 133322

TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH A COMBINATION OF B-CELL DEPLETION AND TYROSINE KINASE INHIBITION

EHA Library, Lotte van der Wagen, 133323

FIRST-LINE EXTRACORPOREAL PHOTOCHEMOTHERAPY (ECP) FOR ACUTE GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Lucio Morabito, 133324

EFFICACY OF HOST-DENDRITIC CELL VACCINATIONS WITH AND WITHOUT MINOR HISTOCOMPATIBILITY ANTIGEN LOADING, COMBINED WITH DONOR LYMPHOCYTE INFUSION IN MULTIPLE MYELOMA PATIENTS

EHA Library, Rimke Oostvogels, 133325

TRACING OF URINARY EXCRETION OF BKV AND JCV BY QUANTITATIVE PCR IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS (ALLO-HSCT) TO ANTICIPATE THE DEVELOPMENT OF HEMORRHAGIC CYSTITIS (HC).

EHA Library, Ana Pilar González Rodríguez, 133326

OUTCOMES AFTER AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS WITH MYC/BCL2 CO-EXPRESSION, DOUBLE-HIT LYMPHOMA, OR MYC COPY GAIN

EHA Library, Alex F. Herrera, 133327

BTLA GENOTYPE AND CLINICAL OUTCOME AFTER HLA-IDENTICAL SIBLING STEM CELL TRANSPLANTATION

EHA Library, Nazly Santos, 133328

HIGH-DOSE VERSUS STANDARD-DOSE RITUXIMAB WITH BEAM IN AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) FOR RELAPSED AGGRESSIVE B-CELL NON-HODGKIN’S LYMPHOMAS (NHL)

EHA Library, Samer Srour, 133329

INTERFERON GAMMA (IFN-GAMMA) NEUTRALIZATION AS A VALUABLE THERAPEUTIC TARGET IN PRIMARY HLH

EHA Library, Franco Locatelli, 133330

BIDIRECTIONAL RELATIONSHIP BETWEEN CMV-R AND AGVHD: CMV-R HAS A BETTER OVERALL SURVIVAL AND T CELL RECONSTITUTION

EHA Library, Pavankumar Varanasi, 133331

HIGH DOSE CHEMOTHERAPY WITH AUTOGRAFT MAY IMPROVE THE POOR PROGNOSIS OF NAIVE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WITH MYC/BCL2 CO-EXPRESSION

EHA Library, Anna Guidetti, 133332

BIOMARKERS PREDICTING ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PROSPECTIVE STUDY IN 120 PATIENTS

EHA Library, Linda Cheyenne Vaccari, 133333

BONE MARROW WT1 LEVELS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT) FOR ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA. STUDY TIME POINTS AND THRESHOLDS WITH CLINICAL RELEVANCE.

EHA Library, Josep Nomdedeu Guinot, 133334

TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONOR IN PEDIATRIC SEVERE APLASTIC ANEMIA: EXPERIENCE WITH TCR ALPHA/BETA AND CD19 DEPLETION AS GRAFT PROCESSING METHOD.

EHA Library, Andrey Abrosimov, 133335

THE PRC2 COMPONENT JARID2 IS DISPENSABLE FOR HEMATOPOIETIC STEM CELLS BUT CRITICAL FOR THE MAINTENANCE OF LEUKEMIC STEM CELLS

EHA Library, Anne-Katrine Frank, 133336

HHEX PROMOTES HSC SELF-RENEWAL AND STRESS HEMATOPOIESIS VIA REPRESSION OF CDKN2A

EHA Library, Jacob T Jackson, 133337

WNT5A FROM THE NICHE REGULATES THE ACTIN REGULATORY PATHWAY IN HEMATOPOIETIC STEM CELLS

EHA Library, Robert A.J. Oostendorp, 133338

NPM1 IS REQUIRED FOR NORMAL HEMATOPOIESIS

EHA Library, Chow Hiang Ang, 133339

PLZF MUTATION ALTERS MOUSE HEMATOPOIETIC STEM CELL FUNCTION AND CELL CYCLE PROGRESSION

EHA Library, Christelle VINCENT-FABERT, 133340

IL-1 INDUCED ACTIVATION OF QUIESCENT HEMATOPOIETIC STEM CELLS IN VIVO

EHA Library, Uta Demel, 133341

SFRP2 FROM THE NICHE IS REQUIRED TO MAINTAIN THE REGENERATION OF THE HEMATOPOIETIC STEM CELL POOL

EHA Library, Robert A.J. Oostendorp, 133342

CLEC-2 EXPRESSION IS A NEW MARKER FOR A SUBSET OF HEMATOPOIETIC STEM/PROGENITOR CELLS THAT CONTRIBUTES TO INFLAMMATION-INDUCED EMERGENT MEGAKARYOPOIESIS

EHA Library, Takahiro Kumode, 133343

IN VITRO AND IN VIVO STEM CELL PROPERTIES OF HIGHLY ENRICHED HUMAN BONE MARROW MESENCHYMAL STROMAL CELLS

EHA Library, Stefan SCHEDING, 133344

GENOME WIDE DYSREGULATION OF GENE EXPRESSION BY TRISOMY 21 IN FETAL LIVER HAEMATOPOIETIC STEM AND PROGENITOR CELLS

EHA Library, Anindita Roy, 133345

GPR56: A NOVEL MOLECULE INVOLVED IN HEMATOPOIETIC STEM CELL GENERATION

EHA Library, Emma de Pater, 133346

DENDRITIC CELL THERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM): FINAL RESULTS OF A PHASE I/II CLINICAL TRIAL

EHA Library, Kirsten Saevels, 133347

EXPLORING CHIMERIC NATURAL KILLER RECEPTOR NKP30 EXPRESSING HUMAN T LYMPHOCYTES FOR ADOPTIVE IMMUNOTHERAPY TO ACUTE LEUKEMIA.

EHA Library, Udo Hartwig, 133348

TARGETING CD123+ ACUTE MYELOID LEUKEMIA CELLS WITH REDIRECTED NATURAL KILLER CELLS

EHA Library, Michael Morgan, 133349